Embecta (NASDAQ:EMBC) Stock Price Down 7.1% – Time to Sell?

Embecta Corp. (NASDAQ:EMBC)’s stock price fell 7.1% during trading on Wednesday . The company traded as low as $12.84 and last traded at $12.6220. 88,615 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 553,146 shares. The stock had previously closed at $13.58.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on EMBC shares. Zacks Research cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. BTIG Research restated a “buy” rating on shares of Embecta in a report on Tuesday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.00.

Embecta Stock Performance

The firm has a market capitalization of $727.55 million, a price-to-earnings ratio of 8.70, a price-to-earnings-growth ratio of 0.81 and a beta of 1.10. The business’s 50 day moving average is $14.05 and its 200-day moving average is $12.48.

Embecta (NASDAQ:EMBC) last released its earnings results on Tuesday, November 25th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.04. The firm had revenue of $263.30 million during the quarter, compared to analyst estimates of $265.66 million. Embecta had a net margin of 7.58% and a negative return on equity of 23.40%. The business’s revenue was down 7.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.45 EPS. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Friday, December 5th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Friday, December 5th. This represents a $0.60 dividend on an annualized basis and a yield of 4.8%. Embecta’s dividend payout ratio (DPR) is 41.96%.

Institutional Investors Weigh In On Embecta

Hedge funds have recently modified their holdings of the business. Larson Financial Group LLC increased its position in Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after acquiring an additional 1,574 shares during the period. Banque Transatlantique SA increased its holdings in shares of Embecta by 879.1% during the 1st quarter. Banque Transatlantique SA now owns 3,701 shares of the company’s stock worth $44,000 after purchasing an additional 3,323 shares during the period. Brooklyn Investment Group raised its position in shares of Embecta by 1,164.1% during the first quarter. Brooklyn Investment Group now owns 3,590 shares of the company’s stock valued at $46,000 after buying an additional 3,306 shares during the last quarter. Wealthquest Corp acquired a new position in shares of Embecta during the first quarter valued at about $48,000. Finally, Picton Mahoney Asset Management bought a new stake in shares of Embecta in the first quarter valued at about $50,000. 93.83% of the stock is owned by institutional investors.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.